[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX339862B - Compuestos imidazopiridinil-aminopiridina substituidos. - Google Patents

Compuestos imidazopiridinil-aminopiridina substituidos.

Info

Publication number
MX339862B
MX339862B MX2013015006A MX2013015006A MX339862B MX 339862 B MX339862 B MX 339862B MX 2013015006 A MX2013015006 A MX 2013015006A MX 2013015006 A MX2013015006 A MX 2013015006A MX 339862 B MX339862 B MX 339862B
Authority
MX
Mexico
Prior art keywords
compounds
substituted imidazopyridinyl
aminopyridine compounds
aminopyridine
methods
Prior art date
Application number
MX2013015006A
Other languages
English (en)
Other versions
MX2013015006A (es
Inventor
Kitamura Takahiro
A Ashwell Mark
Brassard Chris
Filikov Anton
Hill Jason
Koerner Steffi
Lapierre Jean-Marc
Liu Yanbin
Namdev Nivedita
Nicewonger Robert
Palma Rocio
Tandon Manish
Vensel David
Matsuda Akihisa
Iimura Shin
Yoshida Kenichi
Yamazaki Takanori
Isoyama Takeshi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MX2013015006A publication Critical patent/MX2013015006A/es
Publication of MX339862B publication Critical patent/MX339862B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos imidazopiridinil-aminopiridina substituidos y métodos para sintetizar estos compuestos. La presente invención también se refiere a composiciones farmacéuticas que contienen los compuestos imidazopiridinil-aminopiridina substituidos y métodos para tratar trastornos proliferativos celulares, tales como cáncer, al administrar estos compuestos y composiciones farmacéuticas a sujetos con la necesidad de los mismos.
MX2013015006A 2011-06-24 2012-06-21 Compuestos imidazopiridinil-aminopiridina substituidos. MX339862B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500889P 2011-06-24 2011-06-24
PCT/US2012/043501 WO2012177844A2 (en) 2011-06-24 2012-06-21 Substituted imidazopyridinyl-aminopyridine compounds

Publications (2)

Publication Number Publication Date
MX2013015006A MX2013015006A (es) 2014-12-08
MX339862B true MX339862B (es) 2016-06-15

Family

ID=47362419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015006A MX339862B (es) 2011-06-24 2012-06-21 Compuestos imidazopiridinil-aminopiridina substituidos.

Country Status (17)

Country Link
US (2) US8609688B2 (es)
EP (1) EP2723741B8 (es)
JP (1) JP6046710B2 (es)
KR (2) KR101974673B1 (es)
CN (1) CN103748093B (es)
AU (2) AU2012272937B2 (es)
BR (1) BR112013033182A2 (es)
CA (1) CA2837727C (es)
DK (1) DK2723741T3 (es)
ES (1) ES2579855T3 (es)
HK (1) HK1196371A1 (es)
IL (3) IL229719A0 (es)
MX (1) MX339862B (es)
PH (1) PH12013502565B1 (es)
TW (1) TWI561522B (es)
WO (1) WO2012177844A2 (es)
ZA (1) ZA201308929B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
AU2009215188B2 (en) 2008-02-13 2014-09-18 Dana-Farber Cancer Institute, Inc. Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) * 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
JP5926180B2 (ja) 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
WO2011103289A2 (en) * 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
EP2585053A4 (en) 2010-06-25 2014-02-26 Harvard College COMMON RELEASE OF STIMULATING AND HEMMING FACTORS FOR THE PRODUCTION OF TEMPORARY STABILIZED AND SPATULARLY LIMITED ZONES
DK2624873T3 (da) 2010-10-06 2020-03-02 Harvard College Injicerbare, pore-dannende hydrogeler til materiale-baserede celleterapier
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
WO2012149358A1 (en) 2011-04-28 2012-11-01 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US9486512B2 (en) 2011-06-03 2016-11-08 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
KR101974673B1 (ko) * 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
DK2838515T3 (da) 2012-04-16 2020-02-24 Harvard College Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
JP6578298B2 (ja) 2014-03-24 2019-09-18 アークル インコーポレイテッド ３−（３−（４−（１−アミノシクロブチル）フェニル）−５−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン−２−イル）ピリジン−２−アミンを調製する方法
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3653627A1 (en) * 2014-04-22 2020-05-20 ArQule, Inc. Polymorphs of a substituted imidazopyridinyl-aminopyridine compound
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
CA2958770A1 (en) 2014-09-05 2016-03-10 Arqule, Inc. Compositions and methods for treating proliferation disorders
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US11150242B2 (en) 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
CN105315161B (zh) * 2015-06-05 2017-08-04 厦门医学院 一类PKB/Akt抑制剂的关键中间体的制备方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
TW202214631A (zh) * 2020-09-30 2022-04-16 中國商正大天晴藥業集團股份有限公司 作為Akt激酶抑制劑的化合物
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
US20240079084A1 (en) * 2022-08-19 2024-03-07 Atomic Ai, Inc. Methods, systems, and media method applying machine learning to chemical mapping data for rna tertiary structure prediction
WO2024178390A1 (en) * 2023-02-24 2024-08-29 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3722992A1 (de) 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2002859C (en) 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
AU4436196A (en) 1994-12-28 1996-07-19 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
AU3538899A (en) 1998-04-30 1999-11-23 Nippon Chemiphar Co. Ltd. Condensed imidazole derivative and therapeutic agent for liver disease
JP2000344780A (ja) 1998-09-24 2000-12-12 Fuji Photo Film Co Ltd 新規ベンゾピラン化合物、発光素子材料及びそれを使用した発光素子
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
SI1499316T1 (sl) 2002-04-18 2008-08-31 Schering Corp (1-4-piperidinil)benzimidazolni derivati, koristni kot antagonisti histamina H3
AR045134A1 (es) 2003-07-29 2005-10-19 Smithkline Beecham Plc Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005021544A2 (en) * 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine-derivatives as c-kit inhibitors
CA2669736C (en) 2005-11-03 2017-02-21 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
BRPI0620386A2 (pt) 2005-12-21 2011-12-20 Schering Corp composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
DE602007004092D1 (de) 2006-03-22 2010-02-11 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
CN100398540C (zh) 2006-04-03 2008-07-02 大连理工大学 芳杂环基咪唑并萘酰亚胺类化合物及其应用
MY157033A (en) 2006-07-11 2016-04-15 Dae Woong Pharma Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
CA2679809A1 (en) 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
TW200932872A (en) 2007-10-17 2009-08-01 Cheil Ind Inc Novel compound for organic photoelectric device and organic photoelectric device including the same
KR20090007347U (ko) 2008-01-16 2009-07-21 춘-치 왕 가속 페달 포지션 센서를 구비한 자동차용 연료 공급 기구
US8501770B2 (en) * 2009-12-30 2013-08-06 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
KR101974673B1 (ko) * 2011-06-24 2019-05-02 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds

Also Published As

Publication number Publication date
DK2723741T3 (en) 2016-06-06
EP2723741A2 (en) 2014-04-30
KR20140040773A (ko) 2014-04-03
KR101974673B1 (ko) 2019-05-02
TW201311687A (zh) 2013-03-16
EP2723741B8 (en) 2016-09-21
HK1196371A1 (zh) 2014-12-12
AU2012272937A1 (en) 2013-12-19
JP2014517072A (ja) 2014-07-17
US8609688B2 (en) 2013-12-17
KR20190015600A (ko) 2019-02-13
TWI561522B (en) 2016-12-11
PH12013502565A1 (en) 2017-05-29
WO2012177844A3 (en) 2013-04-04
PH12013502565B1 (en) 2017-05-29
US20140073635A1 (en) 2014-03-13
IL286152A (en) 2021-10-31
AU2016269408B2 (en) 2018-04-05
US8962619B2 (en) 2015-02-24
IL265897A (en) 2019-06-30
BR112013033182A2 (pt) 2016-09-06
CN103748093B (zh) 2016-06-01
CA2837727C (en) 2019-12-03
EP2723741B1 (en) 2016-04-27
WO2012177844A2 (en) 2012-12-27
IL229719A0 (en) 2014-01-30
US20120329791A1 (en) 2012-12-27
AU2016269408A1 (en) 2016-12-22
ES2579855T3 (es) 2016-08-17
CN103748093A (zh) 2014-04-23
EP2723741A4 (en) 2014-12-03
JP6046710B2 (ja) 2016-12-21
ZA201308929B (en) 2016-03-30
CA2837727A1 (en) 2012-12-27
IL265897B (en) 2021-09-30
MX2013015006A (es) 2014-12-08
AU2012272937B2 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX344530B (es) Compuestos de benceno substituido.
PH12015500825A1 (en) Substituted benzene compounds
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
MX2015006152A (es) Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
WO2011082271A3 (en) Substituted triazolo-pyrimidine compounds
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
WO2012088491A3 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
WO2011082269A3 (en) Substituted benzo-pyrimido-tetrazolo-diazepine compounds
MX2012007471A (es) Compuestos substituidos de pirrolo-aminopirimidina.
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
FG Grant or registration